Laura Jones and Justin Gallagher report on Medicare's decision to cover LDCT screening, trabectedin in soft tissue sarcoma, and the link between coffee intake and a reduction in endometrial cancer risk.

The panelists, Brian Van Tine, MD, PhD; Shreyaskumar Patel, MD; Robin L. Jones, MD, MRCP; Jonathan Trent, MD, PhD; and Andrew Wagner, MD; discuss phase I/II data with olaratumab and its mechanism of action.

William D. Tap, MD, chief, Sarcoma Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the mechanism of action of olaratumumab as a treatment for patients with soft tissue sarcoma.

The ABC's of a Sarcoma Diagnosis

This session highlighted key concepts for people who are newly diagnosed with sarcoma. Dr. Brittany Siontis gave an overview of sarcomas including types, incidence, diagnostic tests, and potential treatments. She shared her insights on what this diagnosis means for patients. Ms. Annie Achee shared her lived experience on the ABCs of a new diagnosis including Awareness, Be your best advocate and Communicate your needs.

Panelists William D. Tap, MD; Damon Reed, MD; Mark Agulnik, MD; Martee L. Hensley, MD; George D. Demetri, MD; and Shreyaskumar Patel, MD, provide insight on the factors that guide treatment decisions in second-line and subsequent lines of therapy in soft tissue sarcomas.

A video produced by Link Studio, a board certified medical illustration and animation studio, for Parkview Cancer Institute.

Chapters: Soft Tissue Sarcomas
00:00 - What are Soft Tissue Sarcomas?
00:51 - Unplanned Surgical Excision
01:49 - Types of Tissue Biopies
02:01 - Image-Guided Needle Biopsy
02:22 - Surgical Incisional Biopsy
03:19 - 5 Year Survival Rate

The panelists, Brian Van Tine, MD, PhD; Shreyaskumar Patel, MD; Andrew Wagner, MD, PhD; Robin Jones, MD, MRCP; Lor Randall, MD, FACS; and Jonathan Trent, MD, PhD; share their final thoughts on recent advancements and future directions in soft tissue sarcoma.

William D. Tap, MD; Kristen N. Ganjoo, MD; Jonathan C. Trent, MD, PhD; Victor M. Villalobos, MD, PhD; and Richard F. Riedel, MD, discuss their personal approaches regarding the use of systemic therapy for metastatic soft-tissue sarcoma and when to use chemotherapy alone versus doxorubicin with olaratumab.

Prof Ian Judson

Clinical medical oncologist

The latest new treatment - Trabectedin (Yondelis®) for metastatic or advanced soft tissue sarcoma